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Background: There is limited head-to-head data on long-term safety and efficacy outcomes for everolimus-eluting stent (EES) and sirolimus-
eluting stent (SES).
methods: In the SORT OUT (Scandinavian Organization for Randomized Trials with Clinical Outcome) IV trial we prospectively randomized 2,774 
patients. The SORT OUT IV trial demonstrated non-inferiority of the EES to the SES at 9 months. Follow-up through 4 years was complete in 2,770 
(99.9%)). The 4-year pre-specified endpoint was a composite of safety and efficacy (major adverse cardiac event (MACE): cardiac death, myocardial 
infarction, target vessel revascularization and definite stent thrombosis).
results: At 4-year EES was superior to SES for the composite end point which occurred in 11.8% in the EES group and in 14.7% in the SES group 
(hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.65-0.98). Cardiac death (EES 3.8% vs. SES 3.9% (HR 0.98, 95% CI 0.67-1.43)) did not differ 
between the two groups, whereas target lesion revascularization (EES 4.2% vs. SES 6.2%, (HR 0.68, 95% CI 0.49-0.95)), myocardial infarction (EES 
2.9% vs. SES 4.3%, (HR 0.67, 95% CI 0.45-1.00)) and definite stent thrombosis (EES 0.3% vs. SES 2.0%, (HR 0.15, 95% CI 0.05-0.45)) were lower in 
the EES group.
Conclusions: At 4-year follow-up, MACE rate was significantly lower in EES treated patients compared to SES. A better safety and efficacy was 
found with the EES with reduced risk of myocardial infarction, definite stent thrombosis and target lesion revascularization.
